BRCA1 rs121918409: Understanding Hereditary Cancer Risk Variants
The rs121918409 variant is a rare genetic alteration located within the BRCA1 gene. It is classified as a pathogenic variant associated with an increased risk of developing hereditary breast and ovarian cancer syndrome.
What each genotype means
Typical BRCA1 profile
This genotype represents the common, non-variant sequence at this specific location in the BRCA1 gene. It is not associated with the increased hereditary cancer risks linked to the pathogenic variant. This result does not rule out other genetic or environmental factors that may influence cancer risk.
This is the most common genotype found in the general population across all ancestries.
Increased hereditary cancer risk
This genotype indicates the presence of a pathogenic variant in the BRCA1 gene, which is associated with an increased lifetime risk of developing hereditary breast and ovarian cancer. Because this variant affects DNA repair mechanisms, individuals with this result should consult with a genetic counselor or healthcare provider to discuss personalized screening and management strategies. This is not a diagnosis of cancer, but rather an indicator of elevated susceptibility.
This genotype is very rare in the general population.
Increased hereditary cancer risk
This genotype indicates the presence of two copies of the pathogenic variant in the BRCA1 gene. Research suggests that carrying this variant is linked to a significantly higher lifetime risk of hereditary breast and ovarian cancer compared to the general population. Please discuss these findings with a medical professional or genetic specialist to understand the implications for your health and potential clinical management.
This genotype is extremely rare and is not typically observed in the general population.
What is rs121918409?
The identifier rs121918409 refers to a specific genetic variant found within the BRCA1 gene. In genetics, an rsID (reference SNP cluster ID) is a unique label used by researchers to track a specific location in the human genome where a variation may occur. This particular variant is a change in the DNA sequence that has been identified as pathogenic, meaning it is known to disrupt the normal function of the gene. Because it is located in a critical region of the BRCA1 gene, it can interfere with the body's ability to produce functional proteins necessary for maintaining genomic stability. Understanding where this variant sits is essential for clinical geneticists who evaluate how specific changes in the DNA code might impact overall health and disease susceptibility.
The Role of the BRCA1 Gene
The BRCA1 gene, which stands for Breast Cancer gene 1, provides instructions for making a protein that acts as a tumor suppressor. This protein is a vital component of the BRCA1-associated genome surveillance complex, which helps repair damaged DNA and ensures that cells divide properly. When the BRCA1 gene is functioning correctly, it prevents cells from growing and dividing too rapidly or in an uncontrolled way. However, when a pathogenic variant like rs121918409 is present, the resulting protein may be truncated or non-functional. This loss of function impairs the cell's ability to repair DNA damage, which can lead to the accumulation of further genetic mutations. Over time, this instability increases the likelihood that cells will become cancerous, particularly in breast and ovarian tissues.
Research and Clinical Associations
Scientific research has established a strong link between pathogenic variants in BRCA1 and an increased risk of hereditary breast and ovarian cancer syndrome. Individuals who carry these variants have a significantly higher lifetime risk of developing these cancers compared to the general population. The evidence for the pathogenicity of specific BRCA1 variants is often derived from large-scale clinical databases and family studies that track cancer incidence across generations. While the association between BRCA1 dysfunction and cancer is well-documented, the specific clinical impact of any single variant can vary based on its location within the gene. Clinicians use this information to provide personalized risk assessments and to guide screening protocols, such as more frequent mammograms or prophylactic measures, for individuals identified as carriers.
Population Frequency
The rs121918409 variant is considered very rare in the general population. Because it is not a common polymorphism, it is not typically found in large-scale population studies at high frequencies. Its rarity means that it is primarily identified through targeted clinical genetic testing in individuals with a personal or family history of cancer, rather than through general population screening.
What You Can and Cannot Do With This Information
If you have been informed that you carry a variant like rs121918409, it is important to understand that this information is for educational purposes and does not constitute a medical diagnosis. Genetic test results should always be interpreted by a qualified healthcare professional, such as a genetic counselor or an oncologist, who can place the finding in the context of your personal and family medical history. You cannot use this information to self-diagnose or to make independent decisions about medical treatments or surgeries. Instead, use this knowledge to facilitate a productive conversation with your doctor. They can help you understand your specific risk profile and discuss appropriate surveillance or risk-reduction strategies tailored to your health needs.
How common is this variant?
The rs121918409 variant is documented as very rare across all major ancestral populations.
Frequently asked questions
What does it mean if I have a BRCA1 variant?
A pathogenic BRCA1 variant means there is a change in the gene that affects its ability to suppress tumor growth. This is associated with a higher lifetime risk of certain cancers, but it does not mean a cancer diagnosis is inevitable.
Is rs121918409 the same as other BRCA1 mutations?
No, rs121918409 is a specific, unique genetic change. While it belongs to the same gene as other BRCA1 mutations, every variant has its own specific clinical classification and impact.
Should I get tested for this variant?
Genetic testing is typically recommended for individuals with a strong family history of breast or ovarian cancer. You should discuss the necessity and implications of testing with a genetic counselor or your primary care physician.
Can I change my risk if I have this variant?
While you cannot change your genetics, you can manage your health risks. This may include increased cancer screening, lifestyle adjustments, or medical interventions, all of which should be discussed with a specialist.
Sources & further reading
Educational information only, last refreshed 10/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121918409?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in BRCA1
This rare variant has been recently annotated in clinical databases as a potential contributor to hereditary breast and ovarian cancer risk.
Variant identified in polygenic risk scores for breast cancer susceptibility.
This variant is a rare genetic alteration in the BRCA1 gene, which is critical for DNA repair and associated with hereditary breast and ovarian cancer syndromes impacting reproductive health.
A very rare variant identified in recent genomic studies, currently being investigated for potential associations with reproductive phenotypes.
A rare variant located in the BRCA1 gene, relevant to reproductive genetic counseling and the assessment of hereditary cancer risk.
This BRCA1 variant (p.Pro871Leu) is a common polymorphism often evaluated in breast cancer risk studies, though it is generally considered to have no clinical significance for hereditary breast and ovarian cancer syndrome.